Compare HOLO & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HOLO | PMN |
|---|---|---|
| Founded | 2018 | 2004 |
| Country | China | Canada |
| Employees | 74 | N/A |
| Industry | Computer Software: Programming Data Processing | Pharmaceuticals and Biotechnology |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.3M | 115.5M |
| IPO Year | N/A | 2022 |
| Metric | HOLO | PMN |
|---|---|---|
| Price | $2.09 | $12.39 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $42.67 |
| AVG Volume (30 Days) | ★ 713.9K | 32.7K |
| Earning Date | 08-10-2023 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.16 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.38 | $0.29 |
| 52 Week High | $12.75 | $27.40 |
| Indicator | HOLO | PMN |
|---|---|---|
| Relative Strength Index (RSI) | 52.16 | 41.11 |
| Support Level | $2.02 | $0.41 |
| Resistance Level | $2.37 | $19.85 |
| Average True Range (ATR) | 0.18 | 1.40 |
| MACD | 0.02 | -0.05 |
| Stochastic Oscillator | 57.69 | 39.09 |
MicroCloud Hologram Inc provides holographic technology services. Its services include holographic light detection and ranging (LiDAR) solutions, holographic LiDAR point cloud algorithms architecture design, technical holographic imaging solutions, holographic LiDAR sensor chip design, and holographic vehicle intelligent vision technology to service customers that provide holographic driver assistance systems (ADAS). The company also provides holographic digital twin technology services for customers and has built a proprietary holographic digital twin technology resource library. MicroCloud's operating segments are: Holographic technology service, which generates maximum revenue, and Holographic solutions. Its revenues are mainly generated in the People's Republic of China (PRC).
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.